COALITION AGAINST SOCIALIZED MEDICINE

a Project of THE CONSERVATIVE POLITICAL ACTION COALITION

June 9, 2026

Via Electronic Delivery

The Honorable Bill Cassidy
Chairman
The U.S. Senate Committee on Health,
Education, Labor, and Pensions
428 Dirksen Office Building
Washington, D.C. 20510

Dear Chairman Cassidy and Members of the Senate Committee on Health, Education, Labor, and Pensions:

On behalf of the Coalition Against Socialized Medicine (CASM), we strongly urge the Committee not to proceed with the Medication Affordability and Patent Integrity Act (S. 2658), which would deter long-term investment in life-saving treatments.

Strong intellectual property (IP) rights are the foundation of the free-market system and a key reason American patients benefit from the latest innovative treatments and technologies. These protections are woven into the fabric of our nation. The Founding Fathers recognized the importance of protecting ideas to drive breakthroughs and advancement. Weakening patent protections would set a dangerous precedent with lasting consequences for American patients who are counting on the next generation of cures.

S. 2658 sets that troubling precedent. By requiring companies to submit confidential Food and Drug Administration (FDA) information to the United States Patent and Trademark Office (USPTO), and penalizing perceived inconsistencies between the two, the bill turns routine regulatory compliance into grounds for invalidating legitimate patents. In doing so, it opens the door to broader IP challenges and undermines the very framework it claims to protect.

Innovation, particularly in the biopharmaceutical industry, is a risky investment that requires significant time, resources, and billions of dollars. To ensure companies are willing to take on that risk, certainty is essential, and strong IP protections are what provide it. When Congress signals that our IP framework is negotiable, it lowers the incentive to develop the therapies and medicines patients need most.

This bill is no exception. By creating new uncertainty around patent protections, lawmakers would send a clear message to innovators: the protections you rely on today may not exist tomorrow. That uncertainty would disrupt the long-term investment decisions behind breakthrough treatments, leaving patients to pay the price.

The Committee should also not proceed with the so-called Biosimilar Red Tape Elimination Act (S. 1954). The legislation, which is completely unnecessary, weakens an important safeguard within the biosimilar approval process. By automatically deeming biosimilars interchangeable without the FDA's established review process, the legislation would bypass an important layer of scientific oversight. Such a change risks undermining confidence in the biosimilar marketplace and could ultimately discourage the very competition supporters claim to promote. A strong and competitive biosimilar market depends on rigorous standards, regulatory certainty, and patient trust—not shortcuts that substitute congressional mandates for scientific evaluation.

We strongly urge the Committee to reject this legislation and instead pursue policies that hold the real bad actors in this process—Pharmacy Benefit Managers (PBMs)—accountable for blocking patient access to existing biosimilars.

Thank you for your time and consideration of this matter.

Sincerely,

Andrew Langer
Executive Director
Coalition Against Socialized Medicine (CASM)